

## Immunoablation of cells expressing the NG2 chondroitin sulphate proteoglycan

Leoni, Giampaolo; Rattray, Marcus; Fulton, Daniel; Rivera, Andrea; Butt, Arthur M.

DOI:

[10.1111/joa.12141](https://doi.org/10.1111/joa.12141)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Leoni, G, Rattray, M, Fulton, D, Rivera, A & Butt, AM 2014, 'Immunoablation of cells expressing the NG2 chondroitin sulphate proteoglycan', *Journal of Anatomy*, vol. 224, no. 2, pp. 216-227.  
<https://doi.org/10.1111/joa.12141>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## METHODS

# Immunoablation of cells expressing the NG2 chondroitin sulphate proteoglycan

Giampaolo Leoni,<sup>1</sup> Marcus Rattray,<sup>2</sup> Daniel Fulton,<sup>3,4</sup> Andrea Rivera<sup>1</sup> and Arthur M. Butt<sup>1</sup><sup>1</sup>*Institute of Biology and Biomedical Sciences, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK*<sup>2</sup>*Bradford School of Pharmacy, University of Bradford, UK*<sup>3</sup>*School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK*<sup>4</sup>*School of Life Sciences, University of Warwick, Warwick, UK*

## Abstract

Expression of the transmembrane NG2 chondroitin sulphate proteoglycan (CSPG) defines a distinct population of NG2-glia. NG2-glia serve as a regenerative pool of oligodendrocyte progenitor cells in the adult central nervous system (CNS), which is important for demyelinating diseases such as multiple sclerosis, and are a major component of the glial scar that inhibits axon regeneration after CNS injury. In addition, NG2-glia form unique neuron–glial synapses with unresolved functions. However, to date it has proven difficult to study the importance of NG2-glia in any of these functions using conventional transgenic NG2 ‘knockout’ mice. To overcome this, we aimed to determine whether NG2-glia can be targeted using an immunotoxin approach. We demonstrate that incubation in primary anti-NG2 antibody in combination with secondary saporin-conjugated antibody selectively kills NG2-expressing cells *in vitro*. In addition, we provide evidence that the same protocol induces the loss of NG2-glia without affecting astrocyte or neuronal numbers in cerebellar brain slices from postnatal mice. This study shows that targeting the NG2 CSPG with immunotoxins is an effective and selective means for killing NG2-glia, which has important implications for studying the functions of these enigmatic cells both in the normal CNS, and in demyelination and degeneration.

**Key words:** glia; immunoablation; immunotoxin; NG2 proteoglycan; oligodendrocyte progenitor cells; oligodendrocyte precursor cells.

## Introduction

The NG2 chondroitin sulphate proteoglycan (CSPG) is expressed in both the developing and adult central nervous system (CNS), where it marks a specific population of glial cells (Butt et al. 2002). A primary function of NG2-glia is to act as oligodendrocyte progenitor cells (OPCs), generating oligodendrocytes during development and in the adult (Rivers et al. 2008; Etxeberria et al. 2010). Most significantly, NG2-glia have been shown to form functional synapses with neurons in hippocampal, cortical and cerebellar slices (Bergles et al. 2000; Lin et al. 2005; Ge et al. 2006; Kukley et al.

2008; De Biase et al. 2010; Etxeberria et al. 2010; Vélez-Fort et al. 2010), and with nodes of Ranvier in white matter (Butt et al. 1999; Kukley et al. 2007; Ziskin et al. 2007; Hamilton et al. 2010). In addition, NG2-glia may also perform a structural function at synapses (Stegmüller et al. 2003). A key aspect of NG2-glia is that they are highly reactive cells and respond to most forms of CNS injury by a rapid increase in proliferation and glial scar formation (Levine et al. 2001; Tan et al. 2005). Notably, NG2 is considered one of the main molecules in the glial scar that contributes to the failure of axon regeneration in the adult CNS (Sandvig et al. 2004; Tan et al. 2005). Neurotransmission may serve as a regulatory mechanism for controlling the developmental progression of NG2-glia (Etxeberria et al. 2010), and a further possibility is that it regulates an injury response in NG2-glia (Hamilton et al. 2010). Hence, regulating NG2-glia has potential significance in normal brain development and function, and in demyelination and degeneration.

The functions of NG2-glia are in part directly related to the properties of the CSPG molecule (Nishiyama et al.

### Correspondence

Arthur Butt, School of Pharmacy and Biomedical Sciences, University of Portsmouth, St Michael's Building, White Swan Road, Portsmouth PO1 2DT, UK. E: arthur.butt@port.ac.uk

Accepted for publication 17 October 2013

Article published online 20 November 2013

1996b; Levine et al. 2001; Stallcup, 2002; Stegmüller et al. 2003). However, a line of NG2-null mice has been produced, and these did not manifest gross phenotypic differences (Grako et al. 1999). Subsequent studies have indicated subtle changes in oligodendrocytes, with a reduction in the numbers and proliferation of OPCs in developing white matter and a delay in myelination in the NG2 null mouse (Kucharova & Stallcup, 2010). However, there are no apparent effects on hippocampal neurogenesis (Thallmair et al. 2006), or on axonal regeneration in the CNS and peripheral nervous system (Hossain-Ibrahim et al. 2007). These genetic studies did not result in the loss of NG2-glia, and so we wished to develop a system that specifically ablates these cells. Immunotoxins have been used successfully for eliminating particular neural populations on the basis of their expression of specific antigens (Wiley, 1996). Here, we demonstrate that as a membrane-spanning molecule, the NG2 CSPG, is an amenable target for selective immunoablation of NG2-expressing glia *in vitro*, and that this secondary immunoablation protocol achieves selective destruction of NG2-glia *in situ* in cerebellar slice organotypic cultures.

## Materials and methods

### Animals and tissue

Experiments were performed on cell lines (C6, CTX-TNA2 and NG108-15) and on cerebellar slices from glial fibrillary acidic protein (GFAP)-enhanced green fluorescent protein (EGFP) transgenic mouse line (Nolte et al. 2001), in which the expression of EGFP was under the control of the human GFAP promoter [line *TgN(GFAP-EGFP) GFEC-FKI*] (gift from Frank Kirchhoff, University of Goettingen). Mice aged postnatal day (P)12 were killed humanely in accordance with the Home Office Animals (Scientific) Act 1986 (UK), and brains were prepared fresh for cerebellar slice cultures or immersion fixed in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for immunohistochemistry.

### Cell lines and culture conditions

C6, CTX-TNA2 and NG108-15 cell lines were obtained from European Collection of Cell Cultures as rat glioma line, transfected astrocytes and mouse neuroblastoma × rat glioma hybrid, respectively. The F98 cell line was obtained from ATCC-LGC Promocell as a rat glioma line. CTX-TNA2 and F98 cells were maintained in culture with Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 5% foetal bovine serum (FBS; Invitrogen); C6 cells with F12 medium (Invitrogen) supplemented with 5% FBS and L-glutamine (Invitrogen) to 2 mM final concentration; NG108-15 cells with DMEM supplemented with 5% FBS, L-glutamine to 2 mM final concentration, 0.6% HAT supplement (Sigma) and with a solution of penicillin–streptomycin (Penicillin G sodium 10 000 U mL<sup>-1</sup>, streptomycin sulphate 1000 µg mL<sup>-1</sup>) diluted 1 : 100. Cells were cultured in an incubator at 37 °C with 5% CO<sub>2</sub> and 95% air; 75-cm<sup>3</sup> flasks were used for maintenance of the cell lines, and 24-well plates were used for experimental purposes. For passaging steps, subconfluent cultures were digested with 0.25% trypsin/EDTA solution (Invitrogen) for 3–5 min, and then resuspended in culture media in a 1 : 10/1 : 20 ratio.

### Cerebellar slice cultures

Cerebellar brain slice cultures were prepared as previously described, with some modifications (Leoni et al. 2009). Brains from P11 to P13 mice were rapidly removed and placed in chilled Gey's balanced salt solution (Invitrogen), supplemented with 25 mM D-glucose. Cerebellar slices were cut at 300 µm using a Mcllwain tissue chopper, and slices were transferred into six-well culture plates with 1 mL serum-free culture medium per well. Medium was composed of Neurobasal™ media (Invitrogen) supplemented with B27 supplement (Invitrogen), with 1 mM glutamine (Invitrogen) and 25 mM D-glucose (Sigma), and a solution of penicillin–streptomycin (Penicillin G sodium 10 000 U mL<sup>-1</sup>, streptomycin sulphate 1000 µg mL<sup>-1</sup>; Invitrogen) diluted 1 : 500. Slices were cultured at 37 °C in 5% CO<sub>2</sub> and 95% air for up to 4 days *in vitro*, and the culture medium was replaced every 2 days. Slices were regularly examined and discarded if contamination occurred. At the end of the experiments, slices were immersion fixed in 4% PFA for 30 min at room temperature (RT) for immunohistochemistry.

### Immunoablation

Cell cultures were exposed to different concentrations of mouse primary anti-NG2 antibody (monoclonal from Upstate), alone or in combination with different concentrations of saporin-conjugated anti-mouse antibody (Mab-ZAP; Advanced Targeting Systems). Both Mab-ZAP and primary antibody were diluted in the culture medium, and the secondary conjugate was added first to avoid internalization of the primary antibody before complexing with the immunotoxin. Control groups included an untreated group (no primary antibody and no secondary immunotoxin), and single-treatment groups, where either one of the two antibodies was presented on its own at different concentrations. For each treatment, representative pictures of the cells were acquired using a digital camera adapted on a Nikon Eclipse TS100 microscope, while cell death was measured using the MTT assay as described below.

Cerebellar slices were treated with two different immunotoxin combinations: (A) NG2/Mab-ZAP, consisting of mouse monoclonal anti-NG2 primary antibody (from Upstate, 1 : 1000), with an anti-mouse secondary antibody linked with the toxin saporin (Mab-ZAP; from ATS, 5 µg mL<sup>-1</sup>); or (B) NG2/Rab-ZAP, consisting of rabbit polyclonal anti-NG2 primary antibody (from Chemicon, 1 : 1000) and anti-rabbit secondary immunotoxin, Rab-ZAP (from ATS, 5 µg mL<sup>-1</sup>); control slices (untreated group) were cultured in culture media. Slices were treated with the anti-NG2-saporin immunococktail for between 2 and 4 days, and sections were analysed by immunohistochemistry (see below).

### Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR)

Cell cultures were examined for NG2 expression using Western blot and RT-PCR. For Western blot, proteins were extracted from the cell cultures with a lysis buffer composed of 50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM EGTA, 0.5 mM phenylmethanesulphonylfluoride, 10 µg mL<sup>-1</sup> leupeptin, 10 µg mL<sup>-1</sup> antipain, 1 µg mL<sup>-1</sup> chymostatin, 1 µg mL<sup>-1</sup> pepstatin A, 5 mM Na<sub>2</sub>P<sub>2</sub>O<sub>7</sub>, 1 mM Na<sub>3</sub>VO<sub>4</sub> and 50 mM NaF. Lysates were centrifuged and supernatants were used for the Stanford colorimetric determination of the total protein content of each sample. Bovine serum albumin was used to make a standard curve and BioRad reagent was used

for the protein assay. The remaining supernatants were mixed with  $5 \times$  Laemmli buffer [312 mM Tris,  $0.1 \text{ g mL}^{-1}$  sodium dodecyl sulphate (SDS), 50% glycerol, 25% mercaptoethanol,  $0.125 \text{ mg mL}^{-1}$  bromophenol blue] to prepare the loading samples for SDS–polyacrylamide gel electrophoresis. The  $50 \mu\text{g}$  of total proteins was run on a 8% polyacrylamide gel and blotted onto nitrocellulose membranes by semi-dry electroblotting at  $1.5 \text{ mA cm}^{-2}$ . Membranes were then blocked for 1 h at RT in a blocking solution consisting of 4% skimmed milk powder dissolved in TRIS-buffered saline (TBS; 150 mM NaCl, 10 mM Tris, pH 7.4) added to 0.05% Tween-20 (TTBS). Membranes were next incubated overnight at  $4^\circ\text{C}$  with a polyclonal anti-NG2 antibody (Chemicon), diluted 1:2000 in blocking solution. The membranes were subsequently washed three times for 5 min in TTBS and then incubated for 1 h at RT in peroxidase-conjugated goat anti-rabbit IgG (1:1000; Sigma). After three further washes for 5 min in TTBS, the membranes were finally processed with the ECL™ Western blot detection system (GE Healthcare) and the Hyperfilm-ECL (GE Healthcare) for the detection of the protein bands. In some cases, clarified homogenates were digested with chondroitinase ABC in order to cleave the GAG lateral chain from the native NG2 proteoglycan. Aliquots ( $150 \mu\text{L}$ ) of homogenates were added to 5 mU of chondroitinase ABC (Seikagaku America) and digested for 30 min at  $37^\circ\text{C}$ . Digested samples were then added to  $5 \times$  Laemmli buffer as described above, and stored at  $-20^\circ\text{C}$  until use.

For RT-PCR, cell cultures were washed twice in PBS and incubated for 5 min with 1 mL RNABee (Biogenesis) per well. Each solution was transferred to Eppendorf tubes, and  $100 \mu\text{L}$  chloroform was added to each tube, shaken by hand and left on ice for 5 min; samples were then centrifuged to obtain upper colourless phase containing the RNA, which was then transferred in new Eppendorf tubes containing  $600 \mu\text{L}$  isopropanol and centrifuged to obtain pellets. 1 mL of 75% ethanol was added to wash the pellet and samples were then centrifuged, ethanol was discarded, and pellets were vacuum-dried for 5 min. The resulting RNA was resuspended in  $35 \mu\text{L}$  RNA resuspension buffer (10 mM Tris pH 8.0, 10 mM NaCl, 1 mM EDTA) at  $65^\circ\text{C}$  in a water bath. About  $5 \mu\text{L}$  aliquots of each sample were used to determine the RNA concentration and purity by determining the  $A_{260}/A_{280}$  ratio with a GeneQuant spectrophotometer. The remaining RNA samples were stored at  $-70^\circ\text{C}$  until use for the reverse transcriptase reaction. About  $1 \mu\text{g}$  RNA of each sample was reverse transcribed into complementary DNA (cDNA) in a final reaction volume of  $20 \mu\text{L}$  containing  $4 \mu\text{L}$   $\text{MgCl}_2$  (25 mM),  $2 \mu\text{L}$   $10 \times$  buffer,  $2 \mu\text{L}$  dNTPs (10 mM),  $0.5 \mu\text{L mL}^{-1}$  oligo d(T)<sub>15</sub>,  $0.5 \mu\text{L}$  RNase inhibitor and  $0.25 \mu\text{L}$  M-MLV Reverse Transcriptase, RNase H minus (all reagents were from Promega). The reaction was carried out at  $42^\circ\text{C}$  for 1 h, followed by 5 min at  $95^\circ\text{C}$ . Negative controls for the PCR reactions were carried out as described above, but omitting the reverse transcriptase and the RNase inhibitor. cDNA samples were stored at  $-20^\circ\text{C}$  until use. The PCR was carried out in a final reaction volume of  $25 \mu\text{L}$  containing  $2.5 \mu\text{L}$  cDNA,  $1.5 \mu\text{L}$   $\text{MgCl}_2$  (25 mM),  $2.25 \mu\text{L}$   $10 \times$  buffer,  $1 \mu\text{L}$  of each forward and reverse primers (both  $2.5 \text{ pmol mL}^{-1}$ , synthesised by Sigma),  $0.125 \mu\text{L}$  dNTPs (10 mM) and  $0.625 \text{ U}$  of Taq DNA polymerase. All reagents were from Promega, except for the primers that were synthesised by Sigma as follows: 5'-CCTCAGAGCCCTATCTCCACGTAGC-3' and 5'-CAT-CACCAAGTAGCCAGCGTTTCG-3' (accession number NM139001). The PCR reactions were performed in a thermal cycler (GeneAmp 9700; Applied Biosystem) with an initial denaturing step of 5 min at  $94^\circ\text{C}$ , and 35 cycles of annealing ( $55^\circ\text{C}$ ), extension ( $72^\circ\text{C}$ ) and denaturation ( $95^\circ\text{C}$ ), 30 s per step. Negative controls of each sample were also amplified in order to test that genomic DNA was absent

from the cDNA samples. PCR products were run on a 1% agarose gel together with a 200-bp DNA ladder (Hyper-Ladder I from Bio-line), and amplified bands were visualised by fluorescence with the SYBR Safe DNA gel stain  $10\,000 \times$  concentrated in dimethylsulphide (Invitrogen), through ultraviolet illumination with UVI/PRO transilluminator system (UVIsoft UVIband Windows Application V10.01).

## Immunolabelling

Cell cultures and cerebellar slices were rinsed once with PBS, and fixed with 4% buffered PFA (pH 7.4) for 30 min at RT. Cells and tissues were washed in PBS, and a blocking stage was performed by incubation for 1 h at RT in blocking buffer composed of 0.1% bovine serum albumin plus 10% normal goat serum and, in the case of brain slices, addition of 1% Triton X-100 in PBS (PBST). Samples were then incubated overnight at  $4^\circ\text{C}$  with primary antibodies diluted in blocking buffer: mouse primary anti-NG2 antibody (monoclonal from Upstate, 1:500); rabbit anti-NG2 (either from Dr Stallcup, 1:500, or Chemicon, 1:200); chicken anti-GFAP (Chemicon, 1:200); rabbit anti-calbindin D-28K (Chemicon, 1:300). After three washes in PBST, samples were incubated for 1 h at RT with the appropriate secondary antibodies conjugated with <sup>488</sup>Alexafluor or <sup>567</sup>Alexafluor (Molecular Probes, 1:500), and in some cases Hoechst dye (Molecular Probes, 1:1000) was used for cell nuclei counterstaining. For double-immunofluorescence labelling, primary antibodies of different origin were diluted together in blocking buffer, and co-dilutions of the appropriate secondary antibodies were used. After final washes in PBST, samples were mounted on poly-lysine-coated glass slides with Vectashield mounting media (Vector Laboratories), and images were acquired using a LSM 5 Pascal Axioskop2 confocal microscope (Zeiss).

## MTT cell death assay

Cell cultures were washed once with  $1 \times$  HBM solution (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 5 mM  $\text{NaHCO}_3$ ,  $1.4 \text{ mM}$   $\text{NaH}_2\text{PO}_4$ ) containing 55 mM glucose and  $0.4 \text{ mM}$   $\text{CaCl}_2$ . The cells were then incubated with  $0.5 \text{ mL}$  per well of  $1.2 \text{ mM}$  MTT [Sigma, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] for 1 h at  $37^\circ\text{C}$ , and the MTT solution was subsequently replaced with  $300 \mu\text{L}$  of dimethylsulphoxide to solubilise the resulting formazan product. Nearly  $200 \mu\text{L}$  aliquots of each sample were finally transferred into 96-well plates, and absorbance measured at 480 nm on a POLARstar Optima microplate reader (BMG LABTECH). Data were statistically analysed with the Origin Lab software. ANOVA was followed by *post-hoc* t-test for comparing individual treatment groups.

## Cell counts and statistical analysis

Two–four images from random fields of view (FOVs;  $460 \times 460 \mu\text{m}$  at  $\times 20$  magnification, or  $230 \times 230 \mu\text{m}$  at  $\times 40$  magnification) from  $n \geq 3$  cerebellar slices were acquired on a LSM 500 confocal microscope (Zeiss), using LSM Image software (Zeiss). Acquisition parameters of magnification, laser energy source and pinhole aperture were kept constant between different treatment groups. Numbers of immunolabelled cells were counted in each FOV, and means ( $\pm$  SEM) calculated for each treatment group. Data were analysed with GraphPad Prism v3.02 software (GraphPad Software), and one-way or two-way ANOVA analysis was performed for all the experimental groups, followed by a *post-hoc* t-test or Tukey's test, as appropriate.




## Results

### Efficacy and specificity of NG2-cell immunoablation *in vitro*

The immunotoxin system is based on a primary anti-NG2 antibody, and a secondary antibody that is directed against the primary antibody and to which the toxin saporin is chemically linked. The primary antibody binds specifically to the epitope on the cell surface, and provides a vehicle for the internalisation of the secondary immunotoxin, resulting in the intracellular release of the toxin saporin and cell death (Wiley, 1996). To develop a specific immunoablation system for NG2-expressing cells, it was necessary to first identify cell lines that strongly expressed NG2 and others that did not express the proteoglycan. Four cell lines were selected on the basis that NG2 CSPG is expressed in glioma cells, but not neurons or astrocytes (Chekenya & Pilkington, 2002), C6 and F98 glioma cell lines, the CTX-TNA2 astrocyte cell line, and the NG108-15 neural cell line. The four cell

lines were characterised for NG2 expression using immunocytochemistry, Western blot and RT-PCR (Fig. 1). The results demonstrate that the C6 and F98 glioma cells expressed high levels of NG2, whereas no NG2 protein was detected either in the astrocytic CTX-TNA2 cell line or in the neuronal hybrid NG108-15 cells. Immunocytochemistry clearly demonstrates that the two glioma cell lines are immunopositive for NG2 (Fig. 1A,B), whereas CTX-TNA2 and NG108-15 cell lines are immunonegative (Fig. 1C,D). This was confirmed by Western blot, where both the 300-kDa core protein and the 400-kDa native form of NG2 proteoglycan were detected in C6 and F98 glioma cells (Fig. 1E); enzymatic digestion of the homogenates with chondroitinase ABC resulted in the complete conversion of the high molecular weight form of NG2 into the 300-kDa one, due to the cleavage of the GAG lateral chain from the core protein, confirming the identity of the protein bands detected. Finally, differential expression of NG2 was demonstrated at the mRNA level by RT-PCR (Fig. 1F), amplified products displaying the predicted size of 502 bp for NG2 mRNA in both C6

**Fig. 1** NG2 expression in cell lines. C6, F98, NG108-15 and CTX-TNA2 cell lines were tested for NG2 expression using immunocytochemistry (A–D), Western blot (E) and RT-PCR (F). (A–D) Cells were immunolabelled for NG2 (green) with a mouse monoclonal antibody from Upstate (1 : 500) and cell nuclei stained with Hoechst 33342 dye (blue). C6 (A) and F98 (B) rat glioma cells express the NG2 antigen on their cell surface, whereas the CTX-TNA2 (C) and NG108-15 (D) cell lines do not express NG2. Scale bar: 50  $\mu$ m. (E) Western blotting revealed protein expression of the NG2 CSPG in the C6 and F98 cell lines, whereas the NG108-15 and CTX-TNA2 cell lines were NG2-negative. The arrows and the arrowheads indicate the 300-kDa core protein and the 400-kDa native form of NG2, respectively, in samples treated (+) with chondroitinase ABC (ChABC), or prior to enzymatic digestion (–). Treatment with ChABC determined the complete conversion of the native form into the 300-kDa form, in both C6 and F98 cell lines. (F) RT-PCR confirmed C6 and F98 cell lines express NG2 mRNA, while NG108-15 and CTX-TNA2 cell lines were negative. A mouse brain extract was used in both Western blot and RT-PCR as a positive control, and molecular weight markers are shown on the left.



and F98 glioma cell lines, whereas no mRNA was detected in the astrocytic CTX-TNA2 cells and was barely detectable in the neuronal hybrid NG108-15 cell line.


On the basis of the expression analyses, the NG2-positive C6 glioma and NG2-negative CTX-TNA2 astrocyte cell lines were used to optimise the secondary immunotoxin protocol. The results show that compared with controls incubation with either the primary anti-NG2 antibody alone (1 : 5000 or 1 : 500 dilutions) or the saporin-conjugated anti-mouse secondary antibody (Mab-ZAP; 1.0, 0.5 or 1.0  $\mu\text{g mL}^{-1}$ ) had no effect on cell densities (Fig. 2A–F) or cell viability, as determined by the MTT assay (Fig. 2G,H;  $P > 0.05$ , one-way ANOVA). Having shown that both primary and secondary antibodies on their own are not toxic for either C6 or CTX-TNA2 cell lines, we examined the combined effect of a range of concentrations of the mouse anti-NG2 and Mab-ZAP antibodies presented together (Fig. 3; Table 1). Cells were examined after 72 h, and in NG2-expressing C6 glioma cells immunoablation occurred in a concentration-dependent manner (Fig. 3), whereas the viability of NG2-negative CTX-TNA2 cells was unaffected by

any of the treatments (Table 1). Thus, only NG2-positive cells were ablated in the presence of both anti-NG2 antibody and the secondary saporin-conjugated secondary


**Table 1** MTT assay for the assessment of the cell viability of CTX-TNA2 cells after treatment with immunotoxin.

	ZAP ( $\mu\text{g mL}^{-1}$ )			
	0	0.1	0.5	1.0
NO $\alpha_1$	1.09 $\pm$ 0.05	0.91 $\pm$ 0.07	0.99 $\pm$ 0.08	0.93 $\pm$ 0.06
$\alpha_1$ (1 : 500)	0.95 $\pm$ 0.05	1.08 $\pm$ 0.06	1.07 $\pm$ 0.14	0.93 $\pm$ 0.04
$\alpha_1$ (1 : 5000)	1.12 $\pm$ 0.09	0.92 $\pm$ 0.05	0.99 $\pm$ 0.05	0.89 $\pm$ 0.07

CTX-TNA2 cells were exposed for 72 h to different combinations of primary anti-NG2 antibody ( $\alpha_1$ ) and secondary immunotoxin ZAP (0–1.0  $\mu\text{g mL}^{-1}$ ). Data represent the MTT turnover, expressed as the MTT product absorbance at 480 nm. None of the treatments had any significant effect on the cell viability of the NG2-negative CTX-TNA2 cell line.



**Fig. 2** Lack of toxicity of either primary or secondary antibodies *in vitro*. (A–F) C6 glioma cells were exposed for 72 h to control culture media (A), or to either anti-NG2 primary antibody ( $\alpha_1$ ) alone (B,C) or saporin-conjugate anti-mouse secondary immunotoxin (ZAP) alone (D–F), at different concentrations. Neither of the two antibodies had any toxicity on the C6 cells, compared with the untreated control group. Scale bar: 100  $\mu\text{m}$ . (G,H) C6 cells (G) and CTX-TNA2 (H) cells were exposed for 72 h to either anti-NG2 primary antibody ( $\alpha_1$ ) or saporin-conjugated anti-mouse secondary immunotoxin (ZAP), at different concentrations, and cell viability measured using the MTT assay. Neither of the two antibodies had any significant toxicity on C6 or CTX-TNA2 cells, compared with the untreated control group. Data are expressed as mean  $\pm$  SEM.



**Fig. 3** Immunoablation of NG2-positive C6 cells. C6 cells were exposed for 72 h to a combination of Mab-ZAP and primary anti-NG2 antibody ( $\alpha_1$ ) at different concentrations. (A–H) Cell density was clearly reduced following treatment with NG2-Mab-ZAP. Scale bar: 100  $\mu$ m. (I) Cell viability measured by the MTT assay was significantly decreased following treatment with the combined NG2-Mab-ZAP. For each treatment,  $n = 4$ . One-way ANOVA analysis ( $P < 0.05$ ) was performed over the three treatment groups. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , *post-hoc t-test* vs. intra-group controls (0 ZAP).

antibody, demonstrating the selectivity and specificity of the NG2-immunotoxin, with greatest cell death using 1 : 5000 dilution of primary antibody and 0.5–1.0  $\mu$ g mL<sup>-1</sup> of saporin-conjugated secondary antibody, consistent with a previous study targeting C6 glioma cells using the 192 IgG primary antibody against the p75<sup>NTR</sup> (Kohls & Lappi, 2000). Interestingly, the 1 : 5000 dilution of primary anti-NG2 antibody was more effective than the higher concentration (1 : 500), most likely due to excess primary anti-NG2 compet-


itively inhibiting the binding of conjugated anti-NG2-saporin to NG2 epitopes and preventing its internalisation into the cells.

### NG2-cell immunoablation in cerebellar slice cultures

The results presented above demonstrated that a combination of primary antibody against NG2 and secondary immunotoxin antibody effectively and selectively killed cultures of NG2-expressing glia, with no indirect effects of either antibody on their own. In cerebellar slices, we used both the mouse anti-NG2 antibody and Mab-ZAP combination (Fig. 4), and the rabbit polyclonal anti-NG2 antibody with a secondary anti-rabbit immunotoxin Rab-ZAP (NG2/Rab-ZAP; Fig. 5). Experiments were performed on cerebellar slices from P12 to P15 GFAP-EGFP mice to identify astrocytes (GFAP-EGFP<sup>+</sup>), in order to confirm the integrity of the slices and the selectivity of NG2 ablation. After 72 h, slices were fixed and immunolabelled for NG2 ( $n \geq 3$  per group). In controls, NG2-glia and astroglia appeared normal, as previously described (Leoni et al. 2009), with NG2-glia being uniformly distributed across the layers of the cerebellum intermingled with Bergmann glia with characteristic morphology, with somata in the Purkinje cell layer, and long primary processes extending through the molecular layer to the pia (Fig. 4A–C). Notably, there was no loss or disruption of NG2-glia following treatment with NG2-Mab-ZAP (Fig. 4D–I), whereas treatment with NG2-Rab-ZAP caused a marked loss of NG2-glia (Fig. 5). Immunolabelling for NG2 was performed following washout of the immunotoxin, and the results from NG2-Mab-ZAP clearly demonstrate that NG2 immunostaining *per se* was not disrupted by incubation in the cocktail (Fig. 4); NG2-glia exhibited their characteristic morphology of small central somata and radially extended fine branching processes (Fig. 4G–I), as described previously (Leoni et al. 2009). The loss of NG2-glia was specific to treatment with the NG2-Rab-ZAP combination (Fig. 5), decreasing from  $60.8 \pm 8.35$  cells per FOV in controls and  $68.5 \pm 7.64$  cells per FOV in NG2-Mab-ZAP, to  $22.0 \pm 3.24$  cells per FOV in NG2/RabZAP (Fig. 5D;  $P < 0.001$ , one-way ANOVA and *post-hoc* Tukey's key test). In addition, NG2-Rab-ZAP had no effect on immunostaining for NeuN and synaptophysin (Fig. 6A,B), or on the general distribution or cell density of EGFP<sup>+</sup> astrocytes (Fig. 6C,D); EGFP<sup>+</sup> astrocytes were surrounded by degenerating NG2-glia and debris in immunotoxin-treated slices (Fig. 6E,F). The results demonstrate that NG2-Rab-ZAP selectively and effectively ablates NG2-glia.

Following treatment with NG2-Rab-ZAP immunotoxin, the bulk of NG2 immunostaining appeared as diffuse and punctate, attributable to debris of dead or dying cells (Figs 5C and 6E). In addition to this substantial loss of NG2-glia, compared with controls surviving NG2-glia appeared degenerative following NG2-RabZAP treatment (Fig. 7A,B); this was analysed further using morphological






**Fig. 4** Mouse anti-NG2 immunotoxin (NG2/Mab-ZAP) does not affect NG2-glia in cerebellar slice cultures. Cerebellar slices from P13 GFAP-EGFP mice were cultured for 4 days *in vitro*, and then fixed and immunolabelled for NG2. Confocal images illustrate the separate channels for NG2 immunolabelling (A,D,G, red), GFP expression (B,F,H, green), and the combined channels (C,F,I). (A–C) Control slices cultured in normal serum-free medium (CTR). (D–I) Slices exposed for 4 days to a combination of mouse anti-NG2 primary antibody and Mab-ZAP secondary antibody (NG2/Mab-ZAP). NG2 immunolabelling (A,D,G) and EGFP astroglial reporter protein (B,E,H) show no substantial toxicity of the treatment to either population of cells. Arrowheads in (A) indicate NG2-immunopositive vascular pericytes, whereas arrows in (F) indicate NG2-glial cells expressing EGFP. Asterisks in (G) and (I) illustrate in detail the morphology of NG2-glial cells that were unaffected by the NG2/Mab-ZAP treatment. These NG2-glial cells were found closely associated with a presumptive Purkinje cell body, indicated by the star in (G–I). GCL, granular cell layer; ML, molecular layer; PCL, Purkinje cell layer.

criteria to subdivide NG2-glia into: (i) normal process bearing cells (Fig. 7C); (ii) amoeboid reactive cells (Fig. 7D); or (iii) severely 'injured' cells characterised by fragmented immunostaining (Fig. 7E). The vast majority of NG2-glia in

control slices ( $n = 44$  cells) were classified as normal (39%) or amoeboid reactive (61%) cells, and no visibly injured cells were identified (Fig. 7F). The situation was reversed following treatment with NG2/Rab-ZAP (Fig. 7G), with 81%






**Fig. 5** Effective immunoablation of NG2-glia in the cerebellum by the NG2/Rab-ZAP immunotoxin. Representative confocal micrographs of cerebellum slices immunolabelled for NG2 after immersion culture for 2 days *in vitro*, in either control conditions (A), a combination of mouse anti-NG2 antibody and Mab-ZAP (B), or rabbit anti-NG2 antibody and Rab-ZAP (C). Only NG2-Rab-ZAP caused ablation of NG2-glia. Scale bars: 20  $\mu\text{m}$ . (D) Cell counts of NG2-immunopositive cells in cerebellum slices expressed as mean number of cells per FOV of 30- $\mu\text{m}$  stack confocal images acquired at fixed acquisition parameters of magnification, laser source energy, pinhole aperture and stack interval (1  $\mu\text{m}$ ). \* $P < 0.05$ , \*\*\* $P < 0.001$ , one-way ANOVA and *post-hoc* Tukey's test.

of surviving NG2-glia appearing severely injured and 16% amoeboid reactive, with very few cells appearing normal (3%). Note that compared with controls, only 30% of cells survived the immunotoxin treatment (Fig. 5D), and the vast majority of these were severely disrupted (Fig. 7G). Furthermore, we have previously reported that NG2-glia begin to express the astroglial EGFP reporter in cerebellar cultures (Leoni et al. 2009), and most of the NG2-glia cells surviving immunotoxin treatment appeared to express the EGFP reporter (Fig. 8), suggesting these cells may be less susceptible to immunoablation.

## Discussion

In the CNS, the NG2 CSPG is strongly expressed in NG2-glia, pericytes and certain gliomas (Butt et al. 2002; Chekenya & Pilkington, 2002; Nishiyama, 2007). One approach to study cellular function is to use genetic ablation, but NG2 knock-out mice did not result in the destruction of NG2-glia and there were only subtle effects on the CNS (Kucharova & Stallcup, 2010). Hence, we strove to develop an immunotoxin approach to target the destruction of NG2-glia *in situ*, using antibodies directed against the NG2 CSPG in



**Fig. 6** Selective immunoablation of NG2-glia. Confocal micrographs of control and immunotoxin-treated (NG2/Rab-ZAP) cerebellum slices. (A,B) Cerebellar slices obtained from P11 wt mice were cultured for 3 days *in vitro* in culture media (A) or Rab-ZAP (B) and then immunolabelled for NeuN (red) and synaptophysin (green), revealing no gross differences between the groups. (C–F) Treatment of P13 cerebellum slices for 3 days *in vitro* from GFAP–GFP mice immunolabelled for NG2 (red), with normal medium (C) or NG2/Rab-ZAP immunotoxin (D–F). There were no gross differences in the number and distribution of astrocytes in the two treatment groups (C,D), and higher magnification shows viable astrocytes surrounded by NG2-immunopositive debris (E), and NG2-glia with fragmented labelling (F).


combination with a secondary immunotoxin conjugated to saporin. The primary antibody targets the extracellular domain of the NG2 CSPG and serves as the vehicle by which the secondary immunotoxin antibody is internalised into the NG2-expressing cells. Our results show that this approach is highly effective for the selective ablation of NG2-expressing cells *in vitro* and *ex vivo* in cerebellar slices.

Immunoablation of NG2-glia was effective after 72 h, consistent with *in vivo* studies examining immunoablation of neurons, which require long-term infusion of immunotoxins via cannulae (Wiley et al. 1991; Kwok et al. 1999; Pizzo et al. 1999). This reflects the time required for the anti-NG2 primary antibody to bind to the cell surface epitope, form a tertiary complex with the secondary immunotoxin, which must then be internalised for saporin to be released, and initiate apoptosis (Wiley, 1996; Kohls et al. 2000). We found the mouse monoclonal anti-NG2-saporin was very effective at selectively ablating NG2-expressing C6 glioma cells *in vitro*, but was totally ineffective in brain slices. The reason for this is unknown, but pre-

sumably the NG2-Mab-Zap complex was not effectively internalised in brain slices, demonstrating the importance of testing multiple antibodies to identify the most efficacious combinations.

The anti-NG2-saporin immunotoxin effectively destroyed NG2-glia without adversely affecting astrocyte or neuronal densities. Furthermore, the vast majority of surviving NG2-glia appeared severely disrupted, possibly in the process of dying. In addition, NG2-glia in cerebellar slice cultures begin to express EGFP astroglial reporter after 48 h (Leoni et al. 2009), and we found that these cells preferentially survived immunoablation at 72 h. These GFAP–EGFP<sup>+</sup>/NG2<sup>+</sup> cells appear to display an astrocyte–oligodendrocyte (AO) lineage phenotype, which has been reported by Kirchhoff and colleagues (personal communication) and is reminiscent of the O-2A cells described by Raff and colleagues (Raff et al. 1983). NG2-glia have been reported to generate astrocytes during development, but do not normally do so in the adult (Zhu et al. 2008). It seems likely that AO cells generated





**Fig. 7** Effect of immunoablation on the morphology of NG2-glia. Cerebellar slices obtained from P12 mice were immersion cultured for 3 days *in vitro* and immunolabelled for NG2. (A) NG2-glia cells in control slices had a characteristic stellate processes-bearing morphology. (B) NG2-glia cell in slice treated with the NG2/Rab-ZAP immunotoxin were severely disrupted and NG2 immunolabelling appeared in 'clumps'. (C,D) NG2-glia in slices treated with the NG2/Rab-ZAP immunotoxin were ranked in three morphological classes, corresponding to process-bearing (C), amoeboid reactive (D), and condensed and fragmented cells (E). (F,G) Pie-chart analysis of the proportions of NG2-glia with the different morphologies expressed as number of cells per FOV of 30- $\mu$ m confocal stack.


in the cerebellar slice are in the process of losing NG2 and gaining GFAP as they differentiate into astrocytes (Leoni et al. 2009), and it is possible that downregulation of the NG2 CSPG protects them from the anti-NG2-saporin immunotoxin.

Our results show it is possible to target NG2-glia *in situ*, and this approach holds promise for studying the effects of NG2-glia cell ablation *in vivo*. Saporin-conjugated immunotoxins have been used to effectively target specific populations of neurons *in vivo*, such as those directed against the p75<sup>NTR</sup> in cholinergic neurons (Wiley et al.

1991, 1995), the dopamine transporter in dopaminergic neurons (Wiley et al. 2003), and a range of other neuronal targets, including the norepinephrine-synthesising enzyme dopamine  $\beta$  hydroxylase, NK1 receptor for the Substance P, the IL-2 receptor, vasopressin and others (Wiley, 1996). Our findings indicate it would be possible to use the same approach to examine the functions of NG2-glia *in vivo*.

In summary, our study shows that immunoablation is a feasible option for specifically targeting NG2-glia *in situ*. In light of the potential importance of NG2-glia, it is





**Fig. 8** GFAP-EGFP-expressing NG2-glia survive immunoablation. NG2-glia cells that expressed the astroglial reporter protein GFAP-EGFP displayed resistance to the immunotoxin treatment. (A) Confocal 30-μm z-stack (Ai) and single 1-μm z-sections (Aii, Aiii) illustrating viable NG2-glia expressing the GFAP-EGFP reporter, in the proximity of severely disrupted NG2<sup>+</sup>/EGFP<sup>-</sup> cells. (B) Confocal z-stack of NG2-glia cell expressing the GFAP-EGFP reporter, showing the combined channels (Bi) and single channel analysis of NG2 immunolabelling (Bii) and EGFP expression (Biii). Three-dimensional reconstructions of the NG2<sup>+</sup>/EGFP<sup>+</sup> cell in orthogonal projections (Biv) and following isoforming (Bv) illustrate the cytoplasmic EGFP reporter and cell membrane NG2 immunolabelling.

perhaps surprising, or at the least disappointing, that NG2 knockout mice have failed to reveal any critical effects in the CNS (Thallmair et al. 2006; Hossain-Ibrahim et al. 2007; Kucharova & Stallcup, 2010). However, a comparison can be made with astrocytes, where knockout of GFAP, which characterises astrocytes, did not result in a loss of astrocytes or disrupt their functions (Pekny et al. 1995). The immunoablation approach provides a useful experimental tool for investigating the function of NG2-glia in both physiological and pathological conditions, such as demyelination and degeneration, and could also prove useful in experiments investigating the influence of oligodendroglial cells on cognitive functions, for example learning and memory.

## Acknowledgements

G.L. and A.R. were in receipt of Anatomical Society PhD Studentships. A.M.B. was supported by the MRC and BBSRC, and D.F. by a Science Cities Research Alliance Fellowship and an FP7 Marie Curie Grant (CIG 294051). The authors thank Professor William Stallcup for NG2 antibody, and Frank Kirchoff for the GFAP-GFP mice.

## Author contributions

G.L. performed the experiments, data analysis and preparation of the manuscript. A.M.B. conceived and designed the study, and was responsible for organisation, data analysis and interpretation, and preparing the paper. M.R. contrib-

uted to study design and interpretation, and critical revision of the manuscript and approval of the article. D.F. and A.R. contributed to data interpretation discussions, critical revision of the manuscript and approval of the article.

## References

- Bergles DE, Roberts JD, Somogyi P, et al. (2000) Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. *Nature* **405**, 187–191.
- Butt AM, Duncan A, Hornby MF, et al. (1999) Cells expressing the NG2 antigen contact nodes of Ranvier in adult CNS white matter. *Glia* **26**, 84–91.
- Butt AM, Kiff J, Hubbard P, et al. (2002) Synantocytes: new functions for novel NG2 expressing glia. *J Neurocytol* **31**, 551–565.
- Chekenya M, Pilkington GJ (2002) NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. *J Neurocytol* **31**, 507–521.
- De Biase LM, Nishiyama A, Bergles DE (2010) Excitability and synaptic communication within the oligodendrocyte lineage. *J Neurosci* **30**, 3600–3611.
- Etxeberria A, Mangin JM, Aguirre A, et al. (2010) Adult-born SVZ progenitors receive transient synapses during remyelination in corpus callosum. *Nat Neurosci* **13**, 287–289.
- Ge WP, Yang XJ, Zhang Z, et al. (2006) Long-term potentiation of neuron-glia synapses mediated by  $\text{Ca}^{2+}$ -permeable AMPA receptors. *Science* **312**, 1533–1537.
- Grako KA, Ochiya T, Barritt D, et al. (1999) PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. *J Cell Sci* **112**, 905–915.
- Hamilton N, Vayro S, Wigley R, et al. (2010) Axons and astrocytes release ATP and glutamate to evoke calcium signals in NG2-glia. *Glia* **58**, 66–79.
- Hossain-Ibrahim MK, Rezajooi K, Stallcup WB, et al. (2007) Analysis of axonal regeneration in the central and peripheral nervous systems of the NG2-deficient mouse. *BMC Neurosci* **8**, 80.
- Kohls MD, Lappi DA (2000) Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. *Biotechniques* **28**, 162–165.
- Kucharova K, Stallcup WB (2010) The NG2 proteoglycan promotes oligodendrocyte progenitor proliferation and developmental myelination. *Neuroscience* **166**, 185–194.
- Kukley M, Capetillo-Zarate E, Dietrich D (2007) Vesicular glutamate release from axons in white matter. *Nat Neurosci* **10**, 311–320.
- Kukley M, Kiladze M, Tognatta R, et al. (2008) Glial cells are born with synapses. *FASEB J* **22**, 2957–2969.
- Kwok KH, Law KB, Wong RN, et al. (1999) Immunolesioning of nerve growth factor p75 receptor-containing neurons in the rat brain by a novel immunotoxin: anti-p75-anti-mouse IgG-trichosanthen conjugates. *Brain Res* **846**, 154–163.
- Leoni G, Rattray M, Butt AM (2009) NG2 cells differentiate into astrocytes in cerebellar slices. *Mol Cell Neurosci* **42**, 208–218.
- Levine JM, Reynolds R, Fawcett JW (2001) The oligodendrocyte precursor cell in health and disease. *Trends Neurosci* **24**, 39–47.
- Lin SC, Huck JH, Roberts JD, et al. (2005) Climbing fiber innervation of NG2-expressing glia in the mammalian cerebellum. *Neuron* **46**, 773–785.
- Nishiyama A (2007) Polydendrocytes: NG2 cells with many roles in development and repair of the CNS. *Neuroscientist* **13**, 62–76.
- Nishiyama A, Lin XH, Giese N, et al. (1996b) Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGF. *J Neurosci Res* **43**, 315–330.
- Nolte C, Matyash M, Pivneva T, et al. (2001) GFAP promoter-controlled EGFP-expressing transgenic mice: a tool to visualize astrocytes and astrogliosis in living brain tissue. *Glia* **33**, 72–86.
- Pekny M, Leveen P, Pekna M, et al. (1995) Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. *EMBO J* **14**, 1590–1598.
- Pizzo DP, Waite JJ, Thal LJ, et al. (1999) Intraparenchymal infusions of 192 IgG-saporin: development of a method for selective and discrete lesioning of cholinergic basal forebrain nuclei. *J Neurosci Meth* **91**, 9–19.
- Raff MC, Miller RH, Noble M (1983) A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. *Nature* **303**, 390–396.
- Rivers LE, Young KM, Rizzi M, et al. (2008) PDGFRA/NG2 glia generate myelinating oligodendrocytes and piriform projection neurons in adult mice. *Nat Neurosci* **11**, 1392–1401.
- Sandvig A, Berry M, Barrett LB, et al. (2004) Myelin-, reactive glia-, and scar-derived CNS axon growth inhibitors: expression, receptor signaling, and correlation with axon regeneration. *Glia* **46**, 225–251.
- Stallcup WB (2002) The NG2 proteoglycan: past insights and future prospects. *J Neurocytol* **31**, 423–435.
- Stegmuller J, Werner H, Nave KA, et al. (2003) The proteoglycan NG2 is complexed with alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by the PDZ glutamate receptor interaction protein (GRIP) in glial progenitor cells. Implications for glial-neuronal signaling. *J Biol Chem* **278**, 3590–3598.
- Tan AM, Zhang W, Levine JM (2005) NG2: a component of the glial scar that inhibits axon growth. *J Anat* **207**, 717–725.
- Thallmair M, Ray J, Stallcup WB, et al. (2006) Functional and morphological effects of NG2 proteoglycan deletion on hippocampal neurogenesis. *Exp Neurol* **202**, 167–178.
- Vélez-Fort M, Maldonado PP, Butt AM, et al. (2010) Postnatal switch from synaptic to extrasynaptic transmission between interneurons and NG2 cells. *J Neurosci* **30**, 6921–6929.
- Wiley RG (1996) Targeting toxins to neural antigens and receptors. *Semin Cancer Biol* **7**, 71–77.
- Wiley RG, Oeltmann TN, Lappi DA (1991) Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor. *Brain Res* **562**, 149–153.
- Wiley RG, Berbos TG, Deckwerth TL, et al. (1995) Destruction of the cholinergic basal forebrain using immunotoxin to rat NGF receptor: modeling the cholinergic degeneration of Alzheimer's disease. *J Neurol Sci* **128**, 157–166.
- Wiley RG, Harrison MB, Levey AI, et al. (2003) Destruction of midbrain dopaminergic neurons by using immunotoxin to dopamine transporter. *Cell Mol Neurobiol* **23**, 839–850.
- Zhu X, Bergles DE, Nishiyama A (2008) NG2 cells generate both oligodendrocytes and gray matter astrocytes. *Development* **135**, 145–157.
- Ziskin JL, Nishiyama A, Rubio M, et al. (2007) Vesicular release of glutamate from unmyelinated axons in white matter. *Nat Neurosci* **10**, 321–330.